Suppr超能文献

噬菌体和噬菌体成分疗法对临床微生物学实验室的影响。

Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

机构信息

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

出版信息

J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00229-19. Print 2019 Aug.

Abstract

Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.

摘要

治疗细菌感染的难度正日益增加,因为当前可用的抗菌药物已出现耐药性。这些药物不仅现今的疗效不如过去,而且其使用本身就会选择并继续选择产生更多耐药性。我们必须确定其他管理细菌感染的策略。在这篇综述中,噬菌体疗法被认为是一种很有前途的方法。为了做好这些噬菌体在临床上广泛应用的准备,临床微生物学家可能希望熟悉噬菌体及其抗菌成分,特别是噬菌体的检测方法。在此,我们回顾了 2007 年 1 月至 2019 年 3 月期间与临床微生物学相关的噬菌体和噬菌体编码蛋白治疗的文献。

相似文献

1
Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00229-19. Print 2019 Aug.
2
Clinical Phage Microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy.
Lancet Microbe. 2021 Oct;2(10):e555-e563. doi: 10.1016/S2666-5247(21)00127-0. Epub 2021 Aug 16.
3
Bacteriophages as Therapeutic Preparations: What Restricts Their Application in Medicine.
Biochemistry (Mosc). 2020 Nov;85(11):1350-1361. doi: 10.1134/S0006297920110061.
4
Bacteriophage therapy: recent developments and applications of a renaissant weapon.
Res Microbiol. 2021 Sep-Oct;172(6):103863. doi: 10.1016/j.resmic.2021.103863. Epub 2021 Jul 19.
5
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Clin Ther. 2020 Sep;42(9):1659-1680. doi: 10.1016/j.clinthera.2020.07.014. Epub 2020 Aug 31.
6
Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again.
N Z Vet J. 2018 Sep;66(5):229-235. doi: 10.1080/00480169.2018.1491348. Epub 2018 Jul 16.
7
Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.
Microb Pathog. 2024 Jan;186:106467. doi: 10.1016/j.micpath.2023.106467. Epub 2023 Nov 28.
8
[Bacteriophage Therapy: Retrospective Review and Future Prospects].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Mar;52(2):170-175. doi: 10.12182/20210360207.
9
Current status of clinical trials for phage therapy.
J Med Microbiol. 2024 Sep;73(9). doi: 10.1099/jmm.0.001895.
10
The potential of bacteriophage therapy in the treatment of paediatric respiratory infections.
Paediatr Respir Rev. 2022 Dec;44:70-77. doi: 10.1016/j.prrv.2022.02.001. Epub 2022 Feb 12.

引用本文的文献

2
Treatment of MRSA Infection: Where are We?
Curr Med Chem. 2024;31(28):4425-4460. doi: 10.2174/0109298673249381231130111352.
3
Considerations for the Use of Phage Therapy in Clinical Practice.
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0207121. doi: 10.1128/AAC.02071-21. Epub 2022 Jan 18.
4
Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0187921. doi: 10.1128/AAC.01879-21. Epub 2021 Oct 18.
6
Isolation and Characterization of a New Phage Infecting and Evaluation of Its Therapeutic Efficacy and .
Front Microbiol. 2020 May 13;11:728. doi: 10.3389/fmicb.2020.00728. eCollection 2020.
7
Biological challenges of phage therapy and proposed solutions: a literature review.
Expert Rev Anti Infect Ther. 2019 Dec;17(12):1011-1041. doi: 10.1080/14787210.2019.1694905. Epub 2019 Dec 2.
8
Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.
Curr Infect Dis Rep. 2019 Nov 16;21(12):46. doi: 10.1007/s11908-019-0706-5.

本文引用的文献

1
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.02616-18. Print 2019 Jun.
2
Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection.
Science. 2019 Mar 29;363(6434). doi: 10.1126/science.aat9691.
3
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.
Cell Host Microbe. 2019 Feb 13;25(2):219-232. doi: 10.1016/j.chom.2019.01.014.
7
Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00731-18. Print 2018 Oct.
9
Biotechnological applications of bacteriophages: State of the art.
Microbiol Res. 2018 Jul-Aug;212-213:38-58. doi: 10.1016/j.micres.2018.04.007. Epub 2018 Apr 30.
10
Phage Therapy: What Have We Learned?
Viruses. 2018 May 28;10(6):288. doi: 10.3390/v10060288.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验